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 “The rule is that hypoxia must be treated first, because hypoxia kills quickly while    
hypercapnia kills slowly.” 
 
 JF Nunn, Nunn’s Applied Respiratory Physiology  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my children 
  
ABSTRACT 
Extracorporeal membrane oxygenation provides pulmonary and circulatory support. First abandoned 
from the majority of the intensive care community because of disappointing results in several trials 
(with questionable methods), it experienced a renaissance during the H1N1 influenza pandemic in 
2009/2010. Today, it is a widely accepted therapy option for the sickest respiratory failure patients, 
with survival rates between 50% and 80%, depending on the mode and the center where it is 
performed. But there is still a lack of high quality randomized trials to answer the question whether 
ECMO is superior to conventional mechanical ventilation in severe respiratory failure. But such trials 
are very difficult to perform mainly due to ethical reasons because a randomization to death is not 
acceptable for the majority of health care professionals. The question we have to ask ourselves today 
is not whether ECMO should be performed but how it should be performed, and here there is still a 
lot of work to do. 
In this thesis, several aspects on extracorporeal life support for severe respiratory failure were 
investigated. 
Paper I describes the treatment strategies and short-term outcome of 13 patients with refractory 
severe respiratory failure due to infection with influenza A H1N1 2009 at the ECMO Department at 
the Karolinska University Hospital. All patients survived, and 12 were still alive 3 months after 
discharge from ECMO.  
In paper II the ECMOnet score is presented. It was developed by the Italian ECMOnet, and the 13 
patients treated due to H1N1 infection in paper I were included in an external validation group for 
this score. It has a high accuracy for the prediction of mortality risk in the patients treated with veno-
venous ECMO for H1N1 respiratory failure. The probability of correctly classifying patients with 
this score was 75%, where a score of 4.5 was the most appropriate cutoff for prediction of mortality 
risk. In the external validation group, the score had a good capacity to distinguish survivors from 
non-survivors. 
Paper III is a neurocognitive long-term follow-up study of seven of the patients presented in paper I. 
The studied showed that despite prolonged episodes of hypoxemia, cognitive functioning was normal 
in all patients and that there were no hypoxic cerebral lesions. 
Severe respiratory failure is a hyperinflammatory condition, and neutrophil granulocytes play a key 
role in its development and progress. In paper IV, we explored the hypothesis that the change in 
proportions of mature and immature neutrophils could be used as a prognostic parameter during the 
course of ECMO treatment, but due to a low number of included patients, no strong conclusion could 
be drawn. 
The systematic review presented in paper V is a result of question that arose in paper III, namely 
whether hypoxemia during the course of acute respiratory failure or ECMO treatment per se is 
associated with short- and long-term cognitive dysfunction in survivors. There are no high quality 
studies addressing this question, and it is therefore still not clear whether there is a causal relationship 
between hypoxemia and cognitive impairment. New studies are needed to investigate this important 
question because it is evident that different treatment strategies of acute respiratory failure have an 
impact on survival. 
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1 INTRODUCTION    
 
Severe respiratory failure and the acute respiratory distress syndrome 
In his classic textbook of applied respiratory physiology, the author, JF Nunn, describes severe 
respiratory failure as “a pathophysiological condition that negatively affects the ability of a patient 
to maintain normal arterial oxygen or carbon dioxide partial pressures, which is of pulmonary but 
not cardiac origin” [1].  
This definition agrees with what used in the work by Asbaugh and co-workers, who described a 
new form of respiratory failure in 12 patients admitted to their intensive care unit (ICU) with 
refractory hypoxemia despite substitution of oxygen with (n = 7) or without (n = 3) mechanical 
ventilation. In two patients, the measurements of partial pressure of oxygen and carbon dioxide 
were performed with room air. Table 1 shows the respiratory data in this article. The table was 
reprinted with kindly permission of the Lancet, where the work was published in 1967. 
Table 1. Respiratory characteristics of the 12 reported cases in the paper by Asbaugh and 
colleagues in the Lancet, 1967 
 
Table reprinted with permission of The Lancet.[2] 
The clinical situation was featured by bilateral infiltrates in the chest X-ray of all patients as well 
as low compliance of the respiratory system. Seven of 12 patients died. The authors called it acute 
respiratory distress syndrome (ARDS) as it occurred independently from the cause of respiratory 
failure and without cardiac failure [2]. 
Today the term ARDS is well established in the speciality of intensive care medicine and 
describes a condition of respiratory failure without referring to a specific underlying cause. In a 
recent a publication, ARDS is defined as an inflammatory disorder in the lungs and classified as 
mild, moderate, or severe depending on the severity of hypoxemia, appearance of infiltrates on the 
chest radiogram, and positive end-expiratory pressure (PEEP) settings during mechanical 
ventilation [3]. 
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The four criteria which have to be fulfilled for acute respiratory failure to be termed ARDS 
according the recent definition (“the Berlin definition of ARDS”) are listed below [3, 4]. 
1.   Timing: the onset of respiratory failure may not be older than 1 week. 
2. No lung edema caused by cardiac failure or fluid overload. 
3. Bilateral radiological opacities in the chest X-ray (in severe ARDS the 
 opacities have to be at least in three quadrants). 
4.  Hypoxemia  
- mild ARDS: P/F ratio 201–300 mmHg with a peep ≥ 5 cm H20 
- moderate ARDS: P/F ratio ≤ 200 mmHg, peep ≥ 5 cm H20 
- severe ARDS: P/F ratio ≤ 100 mmHg, peep ≥ 10 cm H20 
  
All studies in this thesis report findings in patients who had developed severe ARDS according to 
above described Berlin definition. Therefore the term severe ARDS will be used in the following. 
Pathophysiology 
According to a classification proposed by Gattinoni et al. I distinguish between pulmonary and 
extrapulmonary ARDS. When the lungs are directly affected from the epithelial side, e.g., in 
bacterial or viral pneumonia, it is called pulmonary ARDS, whereas extra-pulmonary ARDS 
develops from the endothelial side because of primary infectious or inflammatory diseases outside 
of the lungs, i.e., intraabdominal sepsis [5]. However, as already stated above, the etiology of 
severe respiratory failure and ARDS may be different, but the clinical features, which are 
hypoxemia, infiltrates in the chest X-ray, decreased compliance of the respiratory system, and 
need of advanced mechanical ventilation are similar but of different severity depending on the 
category of ARDS. The histological appearance and mechanisms on the cellular level are also 
very similar despite different underlying causes. The histological picture can be divided into an 
acute and a chronic stage, as described in “Nunn’s applied respiratory physiology” [1]. During the 
acute stage, epithelial cells are damaged, which causes intraalveolar and interstitial edema with 
concomitant gas exchange disturbances. In the later phase, called the chronic or fibroproliterative 
stage, damaged or destroyed tissues are repaired. In this stage, thickening of the layers 
(epithelium, endothelium, interstitium) and fibroproliferative rebuilding occur. Interstitial edema 
is still present, and pulmonary function is improving, but still seriously compromised. In the most 
severely ill patients considerable lung-parenchymal and lung function abnormalities are still 
present 1 year after treatment [1, 6, 7]. 
ARDS is an inflammatory condition, and neutrophil granulocytes (polymorphonuclear neutrophil 
= PMN), which are the first line defense cells in acute infection and/or inflammation, seem to play 
an important role in development and maintaining of this syndrome [8,9]. PMNs are attracted by 
specific chemokines, mainly interleukin 8 (IL-8) [8]. The PMNs have surface receptors, CXCR1 
and CXCR2, which have a high affinity for IL-8. The CXCR2 receptor is downregulated in sepsis 
and septic ARDS and therefore PMNs expressing CXCR1 are considered the most important [10]. 
These PMNs migrate from peripheral blood to the pulmonary capillary bed and from there into 
the lung parenchyma where their activation continues by mediators that are released from other 
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inflammatory cells (macrophages, lymphocytes, endothelial cells) but also from other kinds of 
neutrophils [1,8]. Experimental and clinical studies suggest that PMNs not only act as defenders 
against the inflammatory insult, they also contribute to the development and maintaining of 
ARDS itself [8,9,11]. 
The major reasons for the impact of PMNs on the development and progress of ARDS are, as we 
understand them today, an imbalance between the defense against pathogens, with inappropriately 
high release of pro-inflammatory substances (e.g., cytokines, chemokines, and free radicals) 
attracting PMNs to the lungs, and a decreased rate of apoptosis, i.e., programmed cell death 
(PCD), clearing PMNs from the lungs [12]. 
 
Epidemiology of ARDS 
In a recently published observational study, the authors collected patient data from 459 ICUs 
worldwide during a four-week period in the winter of 2014. There were 2377 patients who 
developed ARDS from a total of 29,144 patients admitted to an ICU. Citation from [13]: “The 
period prevalence of mild ARDS was 30.0% (95% CI: 21.7%–25.2%); of moderate ARDS, 
46.6% (95% CI: 44.5%–48.6%); and of severe ARDS, 23.4% (95% CI: 21.7%–25.2%). The 
hospital mortality was 46.1% (95% CI: 41.9%–50.4%) for patients with severe ARDS and the 
overall mortality 40%” [13]. These numbers are similar to the findings from other studies where 
the overall mortality rates ranged from 34% to 43% [14-16].  
 
Treatment 
As stated above, common features of ARDS are hypoxemia with or without hypercapnia. 
Depending on their severity, these patients are treated with either supplemental oxygen during 
spontaneous breathing, non-invasive (NIV), or invasive mechanical ventilation (IMV). High 
ventilatory driving pressures (i.e. the difference between end-inspiratory and end-expiratory 
airway pressures), high end-inspiratory airway pressures, and high tidal volumes during 
conventional mechanical ventilation could further damage the lungs, leading to ventilator-induced 
lung injury (VILI) [17–19]. 
There is some evidence that certain treatment strategies can reduce short- or long-term mortality 
in patients suffering from ARDS: a) mechanical ventilation with lower tidal volumes (VT), b) 
prone positioning, and c) referral to an institution with the possibility to perform extracorporeal 
membrane oxygenation (ECMO) [20-23]. However, a) low VT ventilation has not been studied for 
patients with severe ARDS, b) prone positioning showed only a mortality advantage in patients 
with severe ARDS, and c) ECMO treatment has not been investigated for the mild or moderate 
forms of ARDS.  
 
Despite the fact that mortality from ARDS has decreased over time, it remains still unacceptably 
high, about 40% [14].  
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EXTRACORPOREAL MEMBRANE OXYGENATION 
 
ECMO provides partial or total extracorporeal organ support in case of the most severe forms of 
respiratory, cardiac, or combined cardiorespiratory failure. ECMO is a very invasive, technically 
advanced, and expensive treatment, which requires a certain caseload of at least 30 treatments per 
year to achieve higher survival rates compared to low volume centers [24]. Therefore, in my view, 
only experienced centers should provide ECMO. These centers also need a dedicated 
transportation organization as most patients have to be referred, and a referral on ECMO seems to 
be safer compared to conventional transportation in this category of patients [25]. 
 
Indications and contraindications for respiratory ECMO 
Indications for ECMO are severe refractory hypoxemic or hypoxic respiratory failure with or 
without circulatory failure. In the guidelines from the Extracorporeal Life Support Organization 
(ELSO), it is recommended to consider ECMO when the estimated mortality without ECMO is ≥ 
50%, and ECMO is indicated when the mortality risk is > 80%. Thus, according to this guideline 
ECMO is indicated when the partial pressure of oxygen in the arterial blood is < 100 mmg (7.5 
kPa) with an inspired oxygen concentration of > 90% (P/F ratio < 100 mmHg) [26]. In a recent 
trial, patients were randomized to referral to an ECMO center or conventional treatment with 
transfer when the “Murray” lung injury score > 3. Murray and co-workers developed this score in 
1988 to better classify the severity of lung injury [27]. It takes into account the lung mechanics 
during mechanical ventilation, the degree of hypoxemia, and the occurrence of opacities in the 
chest X-ray (Table 2) 
 
Table 2. The lung injury score developed by Murray et al.  
Table reprinted with permission from the American Journal of Respiratory and Critical Care 
Medicine 
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However, as most patients treated with ECMO do not die because of hypoxemia but due to 
secondary complications, e.g., intracranial bleeding or septic multi-organ failure, oxygenation 
scores are only helpful in the decision when to start ECMO but not in predicting the possible 
outcome of this treatment.  
Other indications for ECMO are refractory hypercapnia despite maximal conventional ventilation 
with a blood pH < 7.2, severe barotrauma with air leakage, or bridge to lung transplantation. 
Contraindications for ECMO are terminal malignancy, known non-recoverable diseases, and 
massive intracranial hemorrhage.  
Other situations, e.g., prolonged mechanical ventilation or immunosuppression, are not any longer 
considered as contraindications and should be evaluated individually. 
  
Technique 
We distinguish between veno-venous and veno-arterial ECMO (v-v ECMO and v-a ECMO). V-v 
ECMO is used for pulmonary support in severe respiratory failure with maintained cardiac 
function and v-a ECMO in patients with severe refractory cardiac or cardiorespiratory failure. The 
patients’ blood is always drained from the venous site of circulation by a centrifugal or roller 
pump (Figures 1 and 2). 
 
Figure 1. ECMO apparatus with centrifugal pump 
. 
 
 
 
 
 
 
 
 
 
centrifugal pump 
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Figure 2. ECMO apparatus with a roller pump head 
 
 
 
The desaturated blood then passes through the artificial lung (the oxygenator) where the gas 
exchange takes place and then it returns either into a vein or an artery depending on the indication 
for ECMO (Figure 3).  
 
Figure 3. v-v and v-a ECMO, flow direction. 
 
Courtesy of Anders Lidén, Lidén Film 2009, Stockholm, Sweden 
 
Today, there are two general methods to cannulate the vessels of a patient for v-v ECMO, either 
with a double lumen cannula, which is usually inserted via the right internal jugular vein, or with a 
two-site cannulation technique where the draining cannula is also inserted via the right internal 
jugular vein and the returning cannula into the right or left femoral vein. The two-site technique is 
roller pump head 
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the preferred cannulation method at the ECMO Department Karolinska. Most centers prefer to 
drain desaturated venous blood via the inferior vena cava and return the saturated blood through 
the superior vena cava into the right atrium. With this approach, it is possible to achieve higher 
saturations due to reduced blood recirculation compared to the technique at the ECMO 
Department Karolinska [28,29]. However, from my clinical experiences, the limitation of the 
former approach is that the total extracorporeal flow, i.e., the level of oxygen delivery by ECMO 
that can be reached, is less with this method than with the method used at the ECMO Department 
Karolinska, particularly in the awake and dehydrated patient, as the venous drainage through the 
IVC is dependent on the hydration of the patient and the intraabdominal pressure. In v-a ECMO 
venous drainage from the superior vena cava instead of from inferior vena cava seems to be 
advantageous with respect to the saturation of the upper body, which has been shown in an 
experimental study [30]. 
 
ECMO Department Karolinska 
The ECMO Department of the Karolinska University Hospital is a six-bed ECMO ICU that is 
dedicated to ECMO treatment of neonatal, pediatric, and adult patients with severe respiratory and 
circulatory failure. Since 1987, more than 1000 patients have been treated here with ECMO. The 
ECMO Center has also performed more than 700 ECMO transports since 1996 when the 
transportation organization was established [31].  
Outcome of ECMO treatment 
In 1989, the Extracorporeal Life Support Organization (ELSO) was founded in the USA. The 
intention was to form an organization for ECMO providing centers and to develop this treatment. 
In 2015, a total of 367 centers were members of the ELSO and data from over 69,000 ECMO 
treatments have been collected in a worldwide database. In the following tables (3–10) from the 
ELSO database, the outcome of ECMO treatment are displayed as international and center-
specific summaries [32]. 
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Table 3. International summary of ECMO treatments: number and category of patients and 
outcome (1989–2015) 
 
 
 
 
Table 4. Center-specific ECMO treatments at the ECMO Department Karolinska: number and 
category of patients and outcome (1989–2015) 
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Table 5. Respiratory treatments in neonatal patients in the international summary: diagnoses and 
ECMO modes. 
 
 
 
 
 
Table 6. Number of ECMO treatments for respiratory failure in neonatal patients at the ECMO 
Department Karolinska: diagnoses and ECMO modes. 
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Table 7. Number of ECMO treatments for respiratory failure in pediatric patients in the 
international summary: diagnoses and ECMO modes. 
 
 
 
 
 
 
Table 8. Number of ECMO treatments for respiratory failure in pediatric patients at the ECMO 
Department Karolinska:  diagnoses and ECMO modes 
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Table 9. Number of ECMO treatments for respiratory failure in adult patients in the international 
summary: diagnoses and ECMO modes 
 
 
 
 
Table 10. Number of ECMO treatments for respiratory failure in adult patients at the ECMO 
Department Karolinska: diagnoses and ECMO modes 
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Influenza A/H1N1 2009 
In April 2009, the World Health Organization (WHO) defined the outbreak of a novel viral 
infection, the swine origin influenza A H1N1 2009 as an international health problem. The first 
infections were diagnosed in Mexico during March 2009, and in June 2009 the WHO declared it a 
pandemic [33].  
In most patients the infection was mild, but in the patients who developed hypoxemic respiratory 
failure and who were in need of ventilatory support in an ICU, the clinical situation quickly  
deteriorated further in many cases, necessitating ECMO treatment. Between 2009 and January 
2016, a total of 53 patients were treated with ECMO at our unit due to confirmed infection with 
influenza A or B. In 45 of these patients, influenza A could be diagnosed and of these 37 had 
influenza A H1N1. It seems that patients with pneumonitis due to infection with H1N1 more often 
develop severe refractory hypoxemic respiratory failure with a need for ECMO compared to other 
types of Influenza A or B. However, to the best of my knowledge, this hypothesis has not been 
scientifically investigated. 
 
Hypoxemia and Hypoxia 
The occurrence of hypoxemia is a common feature in severe ARDS and other conditions with 
severely impaired pulmonary gas exchange. It is defined as a hemoglobin oxygen saturation 
below the normal value. The term “normoxemia” is defined as a PaO2 of 10.7–13.3 kPa (80–100 
mmHg) or a saturation of > 94% at sea level [34,35]. On the other hand, the term hypoxia 
describes a lack of oxygen at the cellular level. Hypoxemia and hypoxia are often mixed up, but it 
is important to keep in mind that they describe two totally different situations. It is possible to 
survive a hypoxemic condition without hypoxia, but it is not possible to survive a long-lasting 
hypoxic condition because “hypoxia kills quickly” [1]. Hypoxemia may not lead to cellular 
hypoxia per se because the physiological compensation of reductions in oxygen saturation will 
keep capillary oxygen content up [36]. Tissue hypoxia is usually caused by an ischemic event, i.e., 
cerebral infarction. Studies of oxygenation in healthy participants on high altitude expeditions 
have shown that it is possible to tolerate hypoxemia quite well [37]. However, there seems to be a 
risk for cerebral lesions and microhemorrhages in association with high altitude, i.e., hypobaric 
hypoxemia [38]. Nevertheless, these conditions are difficult to compare with those seen in 
patients with an underlying disease suffering from hypoxemic respiratory failure. However, in 
these patients, it could be possible to accept hypoxemia as long as the circulation is preserved. 
Unfortunately, it is difficult to define a lower oxygenation threshold that is still acceptable and 
safe, especially if tissue oxygenation is not taken into account [39]. 
 
2 AIMS 
The aims of the presented studies in this dissertation are 
I. To describe the characteristics, clinical features, the treatment, and the short-term outcome 
of 13 patients who were suffering from severe hypoxemic respiratory failure after infection 
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with the pandemic influenza A H1N1 2009 virus and treated with ECMO at the ECMO 
Department Karolinska. 
II. To identify possible predictors of mortality in patients suffering from H1N1 hyoxemic 
respiratory failure who are treated with ECMO. 
III. To investigate the possible effect of permissive hypoxemia on the prevalence of cognitive 
impairment and brain lesions in a long-term follow-up study in survivors from study I. 
IV. To study the hypothesis regarding whether changes in circulating neutrophil subsets during 
ECMO treatment for severe refractory respiratory failure have a diagnostic and/or 
prognostic value. 
V. To systematically review the current literature about the possible relationship between 
hypoxemia and cognitive dysfunction in patients treated with mechanical ventilation or 
ECMO for severe respiratory failure. 
3 MATERIALS AND METHODS 
Ethics 
The local ethical committee of Stockholm approved the studies I–IV. Studies I and II were 
covered by the same ethical approval: DNR-2009/1849-31/2; study III: DNR-2012/986-31/3 and 
study IV: DNR-2011/1282-31/1. Informed consent was obtained by the patients or their relatives 
when the patient was unable to give consent, and in children the consent was obtained by the 
parents. Paper V is a systematic literature review, and for this kind of work no ethical approval is 
needed. 
 
Patients, study methods, and statistics 
I. This study was an observational investigation of all patients with confirmed pandemic influenza 
A H1N1 2009 severe ARDS treated with ECMO at the ECMO Department Karolinska. Patient 
data for evaluation were routinely collected during the treatment and retrospectively analyzed 
after the approval of the local ethics committee and after obtaining informed consent by the 
patients or theire nearest relatives when patients were not able to give consent. The treatment 
modalities, clinical routines at the ECMO Department, and the short-term outcome are described 
in this paper. The data analysis in this study was descriptive, and medians with interquartile 
ranges are presented; no other statistical methods were used. 
 
II. The study for the second paper was performed in Italy by the Italian ECMOnet, which was 
established during the H1N1 pandemic. Data from 60 patients with confirmed or suspected 
influenza A H1N1 infection from 14 ICUs in Italy which had been prospectively collected during 
the pandemic by the Italian ECMOnet were analyzed [40]. With these data a multivariable 
analysis was performed to develop a model to predict morality in patients eligible for ECMO 
treatment because of severe respiratory failure. Variables statistically associated with mortality (p 
≤ 0.25) were included into a univariate analysis. From this, the data with a p = 0.01 were further 
analyzed by multivariate analysis to develop the ECMOnet score. The data from study I were part 
of an external validation group to confirm the results of the Italian patient cohort.  
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III. Long-term survivors of the ECMO-treated patient cohort during the pandemic 2009 were 
invited to participate in a follow-up study 3 years after ECMO treatment. To evaluate their 
cognitive function, a standardized cognitive test battery was applied. These tests were performed 
by a senior psychologist, experienced in testing cognitive functioning. To estimate the arterial 
oxygen content (CaO2) during ECMO the PaO2 was calculated according to to the formula 
published by Severinghaus: Ln PaO2 = 0.385 ln (S-1 - 1)-1 + 3.32 - (72 S)-1 - 0.17 (S6), where S is 
the peripherally measured saturation [41]. Possible hypoxic brain lesions were studied by 
magnetic resonance imaging. The examinations were independently assessed by two senior 
neuroradiologists. The data are displayed as means with  95% confidence intervals (CI) where 
appropriate. 
IV. The proportions of mature (CD16hi) and immature (CD16int) neutrophil granulocytes of the 
total number of CD16 positive cells, serum concentrations of cytokines, chemokines, and 
routinely used inflammatory parameters (c-reactive protein, procalcitonin, and white blood cell 
count) were studied in ECMO patients. Cells in heparinized whole blood from six patients, three 
children and three adults, treated with ECMO for severe ARDS and sepsis and one healthy control 
(HC) were stained with monoclonal antibodies and analyzed by fluorescence-activated cell sorting 
(FACS). Blood samples were analyzed at two different time points, after admission to the ECMO 
department and before decannulation. The time points were named ECMO early and ECMO late. 
The serum concentrations of cytokines and chemokines (Eotaxin, G-CSF, GM-CSF, Fraktalkine, 
IFN-α, IFN-γ, GRO, IL-10, MCP-3, IL-12p40, MDC, IL-15, IL-1Ra, sIL2 Ra, IL-1a, IL-4, IL-5, 
IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1β, TNF-α, TNF-β, VEGF) were analyzed by Luminex at 
the Department of Clinical Immunology of the Karolinska University Hospital. C- reactive 
protein, procalcitonin and white blood cell count (CRP, PCT, WBC) were analyzed daily during 
the entire treatment by the Department of Clinical Chemistry, Karolinska University Hospital. 
The values at the beginning and the end of the ECMO treatment in our unit are displayed. The 
hypothesis was tested with a paired t-test if the Shapiro-Wilk normality test was passed. Changes 
in the other variables were tested with paired t-test or with the Wilcoxon Signed Rank test if the 
normality test failed. The mean with 1 SD of the proportions of CD16hi and CD16int and their 
CXCR1 expression and of serum concentrations of cytokines, chemokines, CRP, PCT and WBCs 
are displayed for the two different time points: ECMO early and ECMO late. When the normality 
test failed, the median with interquartile range (IQR) is displayed. The difference between ECMO 
early and late was considered significant, with a two-tailed p value of <0.05. 
V. It is known that patients with a chronically hypoxemic situation, e.g., chronic obstructive 
pulmonary disease (COPD), can develop cognitive sequelae [42, 43]. As described in paper III, 
the ECMO Center Karolinska accepts lower hemoglobin oxygen saturations during ECMO than 
usually recommended. After the results of the long-term follow-up study in paper III, we 
conducted a systematic review of the current literature to study whether there is proof for the 
hypothesis that hypoxemia in patients with acute severe respiratory failure is responsible for the 
development of short- and long-term cognitive impairment. 
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4 RESULTS 
I  
Between July 20, 2009, and January 12, 2010, 13 patients with H1N1 related severe ARDS were 
treated with ECMO at the ECMO Department of the Karolinska University Hospital (Table 11). 
Median age was 31 years (25–50). Five patients were previous healthy. Five patients presented 
with co-morbidities and had a median body mass index (BMI, kg/m2) of 35 (31–42). A person 
with a BMI of 30 or more is generally considered obese according to the world health 
organization’s (WHO) definition [44].  
 
Table 11 showing patients' characteristics before cannulation for and before decannulation from 
ECMO 
Parameter Pre - ECMO Prior to decannulation 
N  13 13 
Age (years) 31 (25-50)  
Female (pregnant) 5 (3) 5 (2) 
Weight (kg) 88.5 (71-110) 75 (66-105) 
FiO2 1 0.6 (0.46-0.63) 
P/F ratio 52.5 (38-60) 136 (99-226) 
Murray score 3.6 (3.3-4) - 
Vent before ECMO (days) 1 (0.5-7) - 
Pip (cm H2O) 37 (31-38) 25 (22-29) 
Paw (cm H2O) 25 (21-26) 12 (10-13) 
Peep (cm H2O) 17 (15-20) 5 (5-8) 
Tv (ml) 545 (408-617) 577 (381-675) 
Mv (L/min) 12.2 (9.1-15.2) 12.3 (9.8-17.3) 
PaO2 (kPa) 7 (5.1-7.8) 10.7 (8.7-13.1) 
PaCO2 (kPa) 6.3 (5.5-7.6) 5.6 (4.8-6.1) 
SaO2 (%) 86 (70-98) 95 (94-99) 
P/F ratio: ration of arterial oxygen tension and inspiratory oxygen fraction, Pip: peak inspiratory 
pressure, Paw: mean airway pressure, Peep: positive end-expiratory pressure, Tv: tidal volume, 
Mv: minute volume, PaO2: arterial oxygen tension, PaCO2: arterial carbon dioxide tension, SaO2: 
arterial oxygen saturation. 
Median tidal volume in the 13 patients before ECMO was 7.2 mL/kg body weight (IQR 5.4–8.1 
mL/kg). Median number of ventilator days before ECMO was 1 day (IQR 0.57 days). During 
ECMO treatment, as a lung rest strategy, ventilatory pressures and tidal volumes were effectively 
reduced (Figures 4 and 5).  
Twelve patients were cannulated for v-v ECMO at the referring hospital by the ECMO Center's 
transportation team and then transported to our unit by ambulance (n = 7) or fixed wing 
aircraft/ambulance (n = 5).  Two patients were transferred from foreign countries, one from 
Ireland and one from Scotland. One patient was cannulated for v-a ECMO at the Karolinska 
University hospital because of a combination of refractory cardiorespiratory failure. 
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Figure 4. Airway pressures before and during ECMO treatment in 13 patients with severe ARDS 
due to infection with pandemic influenza virus A/H1N1 2009 
 
 
 
Boxplots show the median, interquartile range, outliers, and extreme cases of individual cases. 
Data from one patient before cannulation were missing. 
Figure 5. Tidal volume (VT) before and during ECMO in 13 patients with severe ARDS due to 
infection with pandemic influenza virus A/H1N1 2009 
   
Boxplots show the median, interquartile range, outliers, and extreme cases of individual cases. 
Data from one patient before cannulation were missing. 
cm H2O 
Ventilatory pressures 
VT (ml) 
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A drawback of this strategy is that it often leads to a loss of tidal volumes and end-expiratory lung 
volume, and sometimes it even leads to totally atelectatic lungs, with concomitant decrease of the 
hemoglobin oxygen saturation (Figure 6). 
Figure 6. Boxplot of peripheral arterial saturation 
 
 
Boxplots show the median, interquartile range, outliers, and extreme cases of individual cases. 
Data from one patient before cannulation were missing. 
Complications 
In eight patients, ECMO circuit complications occurred that required interventions: 20 changes of 
the entire ECMO circuit due to coagulation disorders (15 changes) or hemolysis (5 changes); three 
acute changes of the centrifugal pump due to formation of clots resulting in pump stops, two 
changes of the oxygenator because of malfunction, one procedure with evacuation of thrombi in 
the venous cannula, and one change of the raceway in a roller pump due to clot formation. None 
of these complications harmed the patient.  
In one patient, an accidental liver puncture occurred during an attempt to puncture the right pleura 
for fluid drainage. The subsequent hemorrhage could be stopped 72 hours later after several 
laparotomies. Three patients developed pneumothorax and mediastinal emphysema during 
ECMO. Cannulation of the pleura with a large-bore chest drain for the evacuation of air may 
result in significant bleeding according to our experience. Therefore we chose to discontinue 
mechanical ventilation until the air had resolved (Figure 7). 
 
 
 
 
 
SaO2 (%) 
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Figure 7. A patient on v-a ECMO without mechanical ventilation because of right-sided 
pneumothorax. 
 
The median duration of ECMO treatment was 16 days (IQR 9.5–30.5 days). All patients survived 
ECMO, one patient died 4 days after ECMO due to intracranial hemorrhage. Twelve patients 
survived for 3 months after discharge from the ECMO unit. 
II  
Forty-nine of 60 patients included in Italy had confirmed infection with the influenza A/H1N1 
2009 virus. The survival rate was 71% in these patients. The remaining 11 patients without H1N1 
infection had a survival rate of 54%.  
In the univariate analysis, 20 variables were statistically associated with mortality, with a p value 
≤ 0.25 (Table 12). Five predictors of death were then identified by using multivariate analysis: 
preECMO hospital length of stay (OR = 1.52, 95 % CI 1.12-2.07, p = 0.008), bilirubin value (OR 
= 2.32. 95% CI: 1.52–3.52, p < 0.001), systemic mean arterial pressure (OR = 0.92, 95% CI: 
0.88–0.97, p < 0.001, hematocrit value (OR = 0.82, 95% CI: 0.72–0.94, p = 0.008) and creatinine 
level (OR = 7.38, 95% CI: 1.43–38.11, p = 0.02; Table 13). These five parameters were then 
entered into the score. This score was a statistically significant predictor of mortality (OR = 3.44, 
95% CI: 2.04–5.81, p < 0.001). An ECMOnet score of 4.5 was found to have a probability of 
correctly classifying patients of 75%.  
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Table 12. Patient characteristics before ECMO implementation: comparisons between survivors 
and non-survivors 
Variable Total (n = 60) Alive (n = 41) Dead (n = 19) P 
Age, years 40 ± 12.0 38 ± 12.9 43 ± 9.0 0.02 
Gender (male) 36 (60%) 26 (63%) 10 (53%) 0.6 
Height, cm 169 ± 14.7 169± 17.3 168± 6.3 0.8 
BMI, kg/m2 30.5 ± 8.8 30.7 ± 9.6 30.2 ± 6.9 0.8 
BSA, m2 2.01  ± 0.38 2.03 ± 0.43 1.99 ± 0.25 0.6 
PBW, kg 62 ± 11.8 63± 13.3 61± 7.4 0.5 
Weight, Kg 88 ± 28.8 90 ± 32.2 86 ± 20.3 0.5 
H1N1 confirmed  49 (81%) 35 (85%) 14 (74%) 0.1 
PreECMO hospital stay, days 2 (1-5) 2 (1-4) 6 (1-12) 0.02 
Hospital stay, days 39 (24-50) 43 (29-53) 25 (16-45) 0.03 
ICU stay, days 20.5 (14-35) 22 (14-34) 19 (11-43) 0.4 
MV, hours 18.5 (13-35.5) 19 (14-33) 18 (12-44) 0.8 
Transport on ELS 28 (47%) 21 (51%) 7 (37%) 0.2 
COPD 7 (12%) 4 (9.8%) 3 (15.8) 0.5 
Heart disease 1 (1.7%) 1 (2.4%) 0 0.9 
Smoke 8 (13.3) 7 (17.1) 1 (5.3) 0.2 
Diabetes 5 (8.3%) 5 (12%) 0 0.2 
Pregnancy 4 (6.7%) 4 (9.8) 0 0.3 
Neoplasia 1 (1.7%) 1 (2.4%) 0 0.9 
Psychopathology or alcoholic patient 6 (10%) 5 (12%) 1 (5.3%) 0.4 
Rescue therapy: 42 (70%) 29 (71%) 13 (68%) 0.8 
-Recruitment maneuvers 41 (68%) 28 (68%) 13 (68%) 0.9 
-Nitric Oxide 10 (17%) 7 (17%) 3 (16%) 0.9 
-Pronation 16 (28%) 12 (30%) 4 (21%) 0.6 
- Pulmonary vasodilator 5 (8.5%) 2 (4.9) 3 (16.7) 0.2 
Vasoactive amines 20 (33%) 7 (17%) 13 (68%) <0.001 
BIPAP 9 (15%) 7 (17%) 2 (11%) 0.3 
HFOV 4 (6.8%) 2 (4.9%) 2 (11%) 0.4 
Vasoactive and inotropic drugs 37 (65%) 25 (66%) 12 (63%) 0.5 
CPAP-PSV 3 (5%) 3 (7.3%) 0 0.5 
SIMV 2 (3.3%) 2 (4.8%) 0 0.9 
SOFA score 7.8 ± 2.2 7.0 ± 2.2 9.3 ± 3.2 <0.001 
Bilirubin, mg/dl 0.90 (0.61-1.51) 0.80 (0.60-1.10) 1.18 (0.67-1.84) 0.02 
Cardiac Index, l/min/m2 3.7 ± 1.6 3.9 ± 1.9 3.3 ± 1.1 0.1 
Cardiac Output, l/min 7.3 ± 3.1 7.7 ± 3.2 6.6 ± 2.8 0.2 
Creatinine, mg/dl 0.82 (0.65-1.21) 0.80 (0.60-1.08) 0.86 (0.67-1.90) <0.001 
Hematocrit, % 33 ± 5.6 35± 4.7 30 ± 6.8 0.01 
Heart rate, bpm 104 ± 21.0 102.8 ± 21.7 106.6 ± 19.7 0.3 
Respiratory rate, bpm 27 ± 8.1 26 ± 8.7 29 ± 6.4 0.3 
Lactate, mmol/l  1.95 (1.20-2.55) 1.85 (1.20-2.40) 2.07 (1.20-3.00) 0.2 
PaCO2, mmHg 63 ± 20.1 64 ± 22.4 61 ± 14.2 0.6 
MAP, mmHg 77± 15.7 79 ± 16.4 71± 12.3 0,007 
PCV, mmHg 38 (63%) 25 (61%) 13 (68%) 0.6 
PEEP, cmH2O 16 ± 3.8 16 ± 3.2 15 ± 4.9 0.4 
pH 7.3 ± 0.1 7.3 ± 0.1 7.3 ± 0.1 0.5 
Platelet count, x 103/µl 192 ± 125.2 190 ± 92.8 194± 175.1 0.9 
Peak airway pressure, cmH2O 35 ± 6.8 34 ± 5.9 37 ± 8.3 0.2 
Plateau airway pressure, cmH2O 33 ± 4.6 34 ± 5.7 3 ± 2.2 0.1 
Mean airway pressure, cmH2O 25 ± 3.4 25 ± 3.4 26 ± 3.3 0.5 
CVP, mmHg 14 ± 4.7 15  ± 4.0 13 ± 5.6 0.2 
Volume-controlled mechanical ventilation 23 (38%) 15 (37%) 8 (42.1) 0.7 
Vt, ml 405 ± 159.4 417 ± 171.7 379 ± 127.4 0.3 
Minute volume, L 9.8 ± 4.5 9.9 ± 4.4 9.8 ± 4.6 0.9 
Femoral vein-femoral vein configuration 26 (43.3) 20 (48.8) 6 (31.6) 0.2 
Femoral vein-jugular vein configuration 27 (45) 18 (43.9) 9 (47.4) 0.8 
Internal jugular vein-jugular vein configuration 6 (10) 3 (7.3) 3 (15.8) 0.3 
Cannulation-related complications 9 (15) 4 (9.8) 5 (26.3) 0.05 
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 BMI: body mass index; BSA: body surface area; PBW: partial weight bearing; ICU: 
intensive care unit; MV: mechanical ventilation; ELS: extracorporeal life support; COPD: 
chronic obstructive pulmonary disease; BIPAP: bilevel positive airway pressure; HFOV: 
high-frequency oscillatory ventilation; CPAP PSV: continuous positive airway pressure and 
pressure support ventilation; CRRT: continuous renal replacement therapy; SIMV: invasive 
mechanical ventilation synchronized; SOFA: sequential organ failure assessment; PaCO2: 
partial pressure of carbon dioxide; MAP: mean arterial pressure; PCV: pressure control 
ventilation; PEEP: positive end expiratory pressure; CVP: central venous pressure; Vt: tidal 
volume. 
 
Table 13. The ECMOnet score 
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The ROC analysis of the external validation group showed a strong capacity of the ECMOnet 
score to distinguish survivors from non-survivors (c = 0.694, 95 % CI: 0.562–0.862, p = 0.004). 
The accuracy was 62% and sensitivity and specificity were 51% and 76%, respectively (Figure 8) 
Figure 8. ROC curve of the ECMOnet score in the external validation group. 
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III 
13 patients survived ECMO and eleven were still alive 3 years after ECMO. Three out of eleven 
survivors were living abroad and eight in Sweden. We were able to contact one of the three 
patients living abroad and six patients in Sweden. They agreed to participate in this study (n = 7), 
the mean age was 31 years.  
All patients were hypoxemic and five patients had also respiratory or metabolic acidosis at 
initiation of the ECMO treatment (Table 14).  
Table 14. Ventilatory and oxygenation parameters before ECMO. 
Patient # Sex Age 
(years) 
Peep 
(mbar) 
Pip 
(mbar) 
Mean awp 
(mbar) 
P/F ratio 
(mmHg) 
OI Murray 
score 
pCO2 
(kPa) 
pH 
1 m 26 
20 37 missing 54 missing 4 8.0 7,3 
2 f 24 
15 37 23 36 64 4 6.5 7.2 
3 f 31 
20 37 25 51 43 4 4.6 7.3 
4 m 57 
15 43 24 36 67 3.5 6.4 7.4 
5 m 25 
15 34 20 54 37 4 9.4 7.2 
6 m 46 
18 35 26 45 58 4 5.9 7.3 
7 m 34 
16 30 missing 60 missing missing missing missing 
Peep: positive end-expiratory pressure; Pip: peak inspiratory pressure; Mean awp: mean airway 
pressure; FiO2: fraction of inspired Oxygen; P/F ratio: ratio of oxygen partial pressure in arterial 
blood to inspired oxygen fraction, FiO2 = 1.0; OI: oxygenation index. In patient #1 the mean 
airway pressure was not registered before cannulation and in patient #7 the pre ECMO data are 
missing as ECMO was started in another department. 
 
All patients had low saturations compared to traditional goals in severe ARDS but sufficient 
oxygen content and distribution during ECMO treatment (Table 15). Mean CaO2 in the study 
population during the study period was 14.3 ± 1.9 ml/100 ml (mean ± SD) mean Hb 126 ± 8.5 
g/L, mean venous pH 7.37 ± 0.03 and mean body temperature 37.2 ± 0.4°C during the 
observation period. SpaO2 in all seven patients was registered 1191 times during the first 10 
days.  
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 Table 15. Mean values (±SD) of oxygenation parameters, tissue perfusion surrogates and blood 
transfusions during the observation period. 
SvO2: preoxygenator venous saturation in the ECMO system; SpaO2: peripheral measured 
hemoglobin Oxygen saturation; CaO2: arterial oxygen content; ECMO days: duration of ECMO 
from cannulation to decannulation. PRBC: packed red blood cells; ml transfused during the first 
ten days of ECMO treatment or entire treatment if shorter than ten days. Group mean refers to the 
mean value of the individual patients mean values and SD to the standard deviation between 
individual patients mean values. 
Global cognitive functioning (FSIQ and GAI) was at or above the average of 50% of the 
reference population (FSIQ 85-115) in five study patients and in one patient below this average 
(Table 16).  Memory functioning (MI) was normal in all seven study patients when compared to 
age-matched healthy controls. Patient #2 could not be tested with FSIQ due to the lack of formal 
education, which is necessary for FSIQ (Table 16). The four index scores that are the components 
of FSIQ are also displayed.  
 
 
 
 
 
Patient # 
 
SpaO2 % Hb (g l-1) CaO2 (ml dl-1) SvO2 % Lactate (mmol l-1) PRBC 
(ml) 
ECMO 
days 
1 72 ±8 131 ±13 13.2 ±1.7 73 ± 4 1.2 ±0.2 691 ±910 49 
2 74 ±9 122 ±6 12.7 ±1.7 74 ± 5 2.2 ±1.2 262 ±204 23 
3 83 ±5 117 ±7 13.8 ±1,3 76 ± 3 1.2 ±0.6 411 ±611 37 
4 91 ±4 133 ±4 16.6 ±0.7 82 ± 5 1.5 ±0.3 251 ±435 3 
5 75 ±7 120 ±7 12.6 ±1.3 74 ± 5 1.1 ±0.3 447 ±374 16 
6 90 ±4 142 ±8 17.8 ±1.3 73 ± 6 1.5 ±0.3 58 ±143 7 
7 79 ±11 119 ±6 13.2 ±2 69 ± 5 1.1 ±0.3 624 ±651 44 
Group mean 
±SD 
80 ±7.1 126 ±8.5 14.3 ±1.9 74 ± 3.7 1.4 ± 0.4 392 ± 205  
  27 
Table 16. Cognitive and memory function, mean values (95% CI). 
 
Patient # 
Education  
(years) 
 
FSIQ 
 
GAI 
 
MI 
 
VCI 
 
PRI 
 
WMI 
 
PSI 
1 12 102(96-108) 104 (97-110) 107 (100-115) 108 (100-115) 98 (91-105) 105 (97-112) 95 (86-105) 
2 <5 missing missing 108 (100-115) missing missing missing missing 
3 12 79 (74-85) 83 (77-90) 87 (82-96) 89 (82-97) 82 (76-90) 76 (70-85) 76 (70-89) 
4  9 88 (83-94) 93 (87-100) 86 (79-93) 91 (84-99) 98 (91-105) 79 (73-88) 90 (82-101) 
5 20 107 (101-112) 115 (108-121) 125 (116-130) 108 (100-115) 118 (110-124) 122 (113-128) 101 (91-111) 
6 16 96 (91-102) 100 (94-106) 101 (93-107) 95(88-103) 86 (80-94) 113 (105-119) 101 (91-111) 
7 12 95 (90-101) 97 (91-104) 117 (109-123) 91(84-99) 104 (97-111) 108(100-115) 82 (75-94) 
Group 
mean 
 95 (90-101) 99 (93-105) 104 (97-111) 97(90-105) 98 (91-105) 101 (95-109) 91 (82-101) 
FSIQ: Full Scale Intelligence Index (based on the total combined performance of the WAIS-IV subindexes: 
VCI: Verbal Comprehension Index; PRI: Perceptual Reasoning Index; WMI: Working Memory Index;  PSI: 
Processing Speed Index. GAI: General Ability Index (based on the six subtests that the VCI and PRI 
comprise).  MI: Memory Index (based on the total combined performance of Rey Auditory Verbal Learning 
Test, Logical Memory I and II from Wechsler Memory Scale-III and Rey Osterrieth Complex Figure recall).  
The MRI did not show any pathological changes consistent with previous hypoxemia in any 
patient. However, in four patients there were other abnormalities: one patient had a small 
pituitary, one patient had an arachnoid cyst, and two patients had small old cerebral or cerebellar 
infarctions, and in one of these patients the lesions were known before the ECMO episode. 
 
IV 
Due to major problems with sampling and chemical analyses, we were only able to get a full set 
of data in six patients (two children, one adolescent and three adults). Patient characteristics are 
presented in Table 17. 
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Table 17. Patient characteristics before ECMO and outcome 
 
Patient Age (years) Sex Diagnosis P/F ratio (mmHg)  ECMO days Survival to DC 
1 3 F ALL, PCP 56  21 yes 
2 15 F Pneumococcal pneumonia 73  7 yes 
3 72 M Streptococcal group A Pneumonia 57  19 yes 
4 24 F Influenza A, Staph. aureus (PVL) 50  15 yes 
5 9 M Influenza 39  9 yes 
6 62 M Influenza 59  55 no 
ALL: acute lymphatic leukemia; PVL: Panton-Valentine leukocidin; PCP: Pneumocystis jiroveci 
pneumonia; P/F ratio: ratio arterial oxygen tension and inspiratory oxygen fraction (FiO2 = 1) before 
ECMO; DC: discharge from ECMO unit. 
All patients had severe ARDS and sepsis. The median duration of ECMO in the surviving five 
patients was 15 days (IQR = 8–20 days). Blood samples for ECMO early were taken on average 3 
days after cannulation for ECMO (IQR = 1–5.5 days), and for ECMO late after 14 days of 
treatment (IQR = 6.5–18 days) in survivors. In patient #6, who died after 55 days of ECMO, the 
samples were taken day 40 for ECMO early and day 54 for ECMO late. The first sample was 
obtained late after cannulation because the patient was transferred to our department 31 days after 
start of ECMO.  
The percentage of CD16hi PMNs from the total CD16 positive cell count in the analyzed sample 
was lower in the surviving patients compared to the healthy control early after admission to our 
ICU (48% vs. 99%) and had increased to almost normal levels in the surviving group (90%) at the 
end of ECMO treatment (p = 0.03). The percentage of CD16int PMNs from the total CD16 positive 
cell count in the analyzed sample were elevated in the survivors early during ECMO compared with 
the healthy control and decreased significantly during treatment. The differences in CRP, PCT, and 
WBC counts were not statistically significant (Table 18, Figures 9–11). 
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Table 18. CD16 polymorphonuclear leukocytes, their C-X-C chemokine receptor 1 (CXCR1) 
expression, and traditional parameters for the evaluation of the infectious/inflammatory state 
 
* Indicates a statistically significant difference. Mean ± SD are displayed in parentheses. For PCT 
the Wilcoxon signed-rank test was performed; the median and interquartile range (IQR) are 
displayed. 
  
Parameter Healthy control  Survivors early Survivors late p-value Non-Survivor early Non-Survivor late 
WBC x10(9)/L  3.5–8.8  14.2 (8.8) 11.9 (4.9) 0.653 20.5 21.4 
CD16 positive cells (count) - 151 064 (21 573) 125 838 (28393) 0.17 160 713 138 074 
CD16hi (%)  99% 48 (30) 90 (5)* 0.03 79 61 
CD16hi CXCR1 (%) 99% 81  (21) 92 (16) 0,341 98 98 
CD16int (%) 1% 53 (30) 10 (5)* 0.03 21 41 
CD16int CXCR1 (%) 1% 58 (36) 34 (24) 0.174 25 38 
CRP mg l-1 < 3 221.2 (145.8) 135 (121.3) 0.172 315 238 
PCT µg l-1  < 0.5  9.1 (4.3 - 1093) 1.6 (0.5 - 8.9) 0.063 2.8 1.6 
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Figure 9. Light scatter plot from fluorescence activated cell sorting of the proportions of CD16int 
in a survivor (patient #5) and in the non-surviving patient.  
 
The expression of CD16 on PMNs in a survivor (patient 5) and the non-survivor. Mature PMNs 
express high numbers of CD16 (CD16hi) on their surface, while immature PMNs express 
intermediate numbers of CD16 (CD16int). CD16 on PMNs was identified by phycoerythrin (PE)-
labeled CD16 antibodies. The PMNs were identified by CD14 antibodies labeled with fluorescein 
isothiocyanate (FITC).  
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Figure 10. Proportions of mature and immature polymorphonuclear leukocytes (PMNs) in 
ECMO patients after admission and at the end of treatment. 
 
 
% CD16hi: proportions of mature PMNs of CD16 positive cells. %CD16int: proportions of 
immature PMNs of CD16-positive cells. The filled symbols represent the numbers in the non-
surviving patient. 
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Figure 11. Plasma concentrations of plasma C-reactive protein, procalcitonin, and white blood 
cells  
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P-CRP: Plasma C-reactive protein; WBC: White blood cell count (x109/L); PCT: procalcitonin. 
The filled symbols represent the numbers from the non-surviving patient. 
Results of cytokine and chemokine analysis are shown in Table 19.
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Table 19. Cytokines and chemokines in survivors and one non-survivor  
 
 
V 
The search was finalized on 26 August 2016. A total of 2606 articles were found. After removal 
of 781 duplicates, 1825 titles and abstracts were screened. Thirty papers were identified for full 
text assessment. However, no article met the inclusion criteria. A PRISMA 2009 flow chart was 
used for reporting items (Figure 12) [45]. 
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Figure 12. PRISMA 2009 Flow Diagram  
 
 
Six articles reporting case series or describing study questions similar to the one under 
investigation  are described in the review [46-51]. The number of included participants per study 
ranged from 28 to 102; in total, 270 patients completed the investigations. 
Hypoxemia and cognitive dysfunction 
Two of the mentioned studies detected an association between decreased blood oxygenation 
(SaO2 < 90%) and cognitive impairment, while cognitive impairment occurred in all patient 
groups treated for ARF/ARDS with either mechanical ventilation or mechanical ventilation and 
ECMO [46,47].  The percentage of patients with cognitive sequelae ranged from 23% (6 years 
after discharge) to 100% (at discharge).   
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ili
ty
 
Id
en
tif
ic
at
io
n Additional records identified 
through other sources 
(n =  0 ) 
Records after duplicates removed 
(n = 1825) 
Records screened 
(n = 1825  ) 
Records excluded 
(n = 1795   ) 
Full-text articles assessed 
for eligibility 
(n = 30  ) 
Full-text articles 
excluded, with reasons 
(n = 30 ) 
	 
19: no assessment of hypoxia 
5:  no respiratory failure but 
experimental hypoxemia in 
healthy volunteers 
1: review 
1: extracorporeal circulation 
without respiratory failure 
4; case series 
	 
Studies included in 
qualitative synthesis 
(n =  0 ) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 0 ) 
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In the follow-up study by Hopkins et al., no further change in cognitive functioning was detected 
between 1 and 2 years after discharge (45% versus 47% cognitive sequelae, respectively) [46]. 
One study found an association between cognitive dysfunction and a PaO2 of 71 mmHg 
compared to a higher PaO2 of 86 mmHg [51]. Table 20 and 21 show the chracteristics, variable 
definitions and results of the analysed studies. 
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Table 20. Characteristics of the studies  
 
ECMO: extracorporeal membrane oxygenation; ARDS: acute respiratory distress syndrome; P/F ratio: ratio of arterial oxygen partial pressure to fractional inspired oxygen; v-a ECMO: veno-
arterial ECMO; v-v ECMO: veno-venous ECMO; dc: discharge; SaO2: peripheral measured hemoglobin oxygen saturation; OPIE: Oklahoma Premorbid Intelligence Estimation method; 
	
Author, year of publication 
 
 
 
Study design 
 
 
 
Control group Main exposure Study size 
 
 
 
Mean age, years 
 
 
 
Follow up time 
 
 
 
Respiratory failure/ARDS 
stage  
 
Exclusion 
 
Hopkins RO, 2004 
 
 
 
 
 
 
 
Prospective longitudinal  
outcome study 
 
 
 
 
 
 
None 
 
ARDS patients from a 
ventilation trial; duration 
SaO2 <90% 
evaluated: n = 78 
completed dc  
n = 74 
completed 1 year  
follow-up: n = 66 
 
 
 
45.8 (16-81) 
 
 
 
 
 
 
1year 
 
 
 
 
 
 
 
All/P/F ratio ≤150 mmHg 
Premorbid cognitive 
disability, traumatic brain 
injury, neurologic disease, 
psychotic  
disorder 
Rothenhäusler H-B, 2001 
 
 
 
 
 
Case series 
 
 
 
 
 
Normative population 
mean 
ARDS: n = 40 
ECMO: N = 6 
evaluated: n = 119 
included: n = 46  
 
 
 
 
41.5 (+/- 14.7) 
 
 
 
 
 
Median 6 years (range 1-
12 years) 
 
 
 
 
All/unclear 
 
 
 
 
 
none 
 
 
 
 
 
Risnes I, 2006 
 
 
 
Case series 
 
 
 
None 
 
n = 28,  
v-v: n = 12  
v-a: n = 16 
 
n = 28 
 
 
 
37.9 (18.8 - 63.5) 
 
 
 
Mean 5 years (0.5 – 12 
years) 
 
 
11/unclear 
 
 
 
age <18 years 
  
 
 
Hopkins RO, 1999 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case series 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normative population 
mean 
Duration of desaturation 
with SaO2 <90% 
<85% and <80% 
 
enrolled: n = 106  study 
completed at 1 year follow 
up: n=55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45.5 (16 – 78) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dc and 1 year 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All/unclear 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Irreversible disease states, 
1 year survival unlikely, 
enrolled in another study, 
immunosuppression, CNS 
damage, inability to obtain 
informed consent, severe 
ARDS > 21 days, 
malignancy, primary care 
physician refused consent, 
chronic renal failure, 
pregnancy, 
pneumonectomy, chronic 
heart failure 
 
 
 
 
 
Hopkins RO, 2005 
 
 
 
 
 
 
 
 
Longitudinal outcome 
 
 
 
 
 
 
 
 
Premorbid IQ estimation 
with OPIE of the study 
participants  
Duration of desaturation 
SaO2<90% 
evaluated: n = 120, 
included: n = 74 
 
 
 
 
 
 
 
46 (35-57) 
 
 
 
 
 
 
 
 
2 years 
 
 
 
 
 
 
 
 
All/unclear 
 
 
 
 
 
 
 
 
2 with cognitive disability, 
1with Alzheimer’s disease 
 
 
 
 
 
 
 
Mikkelsen ME, 2012 
 
 
 
 
 
Prospective case series 
 
 
 
 
 
Normative population 
mean 
Hypoxaemia, no definition consented: n = 213  tested: 
n = 102  completed all 
domains : n = 75  
 
 
 
49 (40-58) 
 
 
 
 
 
12 month 
 
 
 
 
 
All/unclear 
 
 
 
 
 
None 
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Table 21. Variable definition and results of the described investigations 
 
BGA: blood gas analysis; SaO2: hemoglobin oxygen saturation; IQ: intelligence quotient; v-a ECMO: veno-arterial ECMO; v-v ECMO: veno-venous ECMO; dc: discharge; SKT: short 
cognitive performance test for assessing memory and attention; WAIS-R: Wechsler Adult Intelligence Scale-Revised; WMS-R: Wechsler Memory Scale-Revised; RAVLT: Rey 
Auditory Verbal Learning Test; FSIQ: Full Scale Intelligence Quotient.
	
Author 
 
 
Definition of hypoxaemia 
 
 
Mean time of hypoxaemia 
(hours) 
Definition of cognitive impairment 
 
 
Number and percentage of 
patients with cognitive 
impairment  
Correlation of hypoxemia 
and cognitive impairment 
 
Correlation of ECMO and 
cognitive impairment 
Statistics 
Hopkins RO, 2004 
 
 
SaO2 <90% 
 
 
SaO2 105.9 hours ± 127.6 hours 
<90% 
Two or more tests > 1.5 SD below 
normative population mean or 1 test 
below 2 SD below 
46 of 66 at dc (69.9%) 
30 of 66 at one year (45%) 
At discharge? Not significant 
at 1 year, data not shown 
 
- McNemar 
 
Rothenhäusler H-B, 2001 
 
 
 
not defined 
 
 
 
not defined SKT score of IQ 
 
 
11 of 46 (23.9%)  
 
 
 
not tested 
 
 
 
Not significant, p=0.330 
numbers not shown 
Mann-Whitney U test, 
Wilcoxon signed rank test, 
Kruskal- Wallis test, 
Spearman correlation 
Risnes I, 2006 
 
 
 
 
 
not defined 
 
 
 
 
 
not defined 1 SD below normative population mean 
 
 
 
 
16 of 28 (57%). 
8 of 16 with v-a ECMO 
(50%) 
4 of 12 with v-v ECMO 
(33%) 
 
not tested 
 
 
 
 
 
Not significant, numbers not 
shown 
Wilcoxon signed rank test 
 
 
 
 
Hopkins RO, 1999 
 
 
 
 
 
 
 
 
SaO2 <85% 
 
 
 
 
 
 
 
 
<90% = 122 ± 144 hours 
<85% = 13 ± 28 hours 
<80% = 1 ± 3 hours 
Comparison with corrected t-scores 
from normative population 
 
 
 
 
 
 
55 at dc (100%) 30% 17 of 
55 after 1 year in WAIS-R 
(30%) 
 43 of 55 in WMS-R and 
RAVLT (78%) 
 
 
 
 
PaO2 at enrollment was 
significantly related to 
cognitive outcome 
FSIQ impairment for 
SaO2<90%, p=0.00, SaO2 
<85%, p=0.008, SaO2<80%, 
p=0.013  
 
 
- ANOVA, paired t-test and 
Pearson correlations 
 
 
 
 
 
 
Hopkins RO, 2005 
 
 
 
 
 
 
SaO2<90% 
 
 
 
 
 
 
<90% = 106 ± 128 hour 2 or more test deviation greater than 1.5 
SD or greater 2SD in one test 
 
 
 
 
 
Patients who completed 1 
year follow up: 
46 of 66 at dc (70%) 
30 of 66 at 1 year (46%) 
Patients who completed 2 
year follow up: 
29 of 62 (47%) 
Not significant at 1 and 2 
years of follow up, no p 
value shown 
 
 
 
 
- Descriptive, RMANOVA, 
Pearson correlation 
 
Mikkelsen ME, 2012 
 
 
 
 
 
 
 
 
Not defined 
 
 
 
 
 
 
 
 
unclear Hayling Sentence Completion Test  
Score 
 
 
 
 
 
 
 
41 of 75 (55%) 
 
 
 
 
 
 
 
 
Lower PaO2 was 
significantly associated with 
cognitive impairment at 12 
months (p=0.02). PaO2 was 
no longer significantly 
associated in secondary 
analysis (p=0.32) 
 
 
- Multivariable logistic 
regression 
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ECMO and cognitive dysfunction 
Risnes et al. reported the possible correlation between ECMO treatment and cognitive dysfunction 
in patients treated with ECMO due to ARF or other conditions [48]. Twelve of 28 studied patients 
were treated with veno-venous ECMO (v-v ECMO), 11 of these patients because of respiratory 
failure. Patients treated with veno-arterial ECMO (v-a ECMO) had a higher prevalence of cerebral 
lesions than patients treated with v-v ECMO (75% and 7% cerebral lesions, respectively, p = 
0.0004). Their results showed no direct association between ECMO treatment and cerebral 
dysfunction, but cerebral lesions possibly due to extracorporeal circulation (CPB or ECMO) were 
significantly correlated to the degree of cognitive impairment (p = 0.03). Of the patients treated 
with v-a ECMO, 50% showed neuropsychological impairment compared with 33% in the v-v 
ECMO-treated patients [48].  
Rothenhäusler et al. did not find any indication in their analysis of six cases that ECMO was 
correlated with cognitive impairment when using ECMO as a risk factor [49].  
Study quality 
The grade of evidence in the described investigations was low, because there were no direct 
control groups in any of the studies and no blinded assessment of cognitive impairment. 
Application of the list of study design features confirmed that the described investigations were 
before-and-after studies or case series. Thus, the Cochrane list of bias and the Newcastle-Ottawa 
scale tables were not applicable. 
One report had cognitive impairment at study start as an exclusion criterion [50]. The other 
investigations did not explicitly have a measure to exclude cognitive impairment at study start. The 
cognitive impairment as outcome was not blindly assessed. 
However, the follow-up time was longer than 6 months in all investigations and the drop out lower 
than 20% in five of six studies.  
 
5 DISCUSSION 
The articles presented in this thesis showed that ECMO is a feasible treatment option in patients 
with pandemic -influenza A / H1N1 2009-induced refractory severe ARDS with a good short- and 
long-term survival (papers I and III). The Italian EMOnet developed a preECMO morbidity score 
that showed that the mortality in ECMO-treated H1N1 patients is associated with preECMO 
extrapulmonary organ function. In this study, the patients from paper I were part of an external 
validation group (paper II). Seven of 11 survivors were followed up with an extensive test battery 
to study their cognitive function 3 years after ECMO. The intelligence quotient (FSIQ) and 
memory function (MI) were all normal despite prolonged hypoxemia during ECMO (paper III). In 
a systematic review of the current literature, no evidence could be found for the hypothesis that 
hypoxemia and/or ECMO per se have an impact on cognitive outcome in survivors from severe 
respiratory failure (paper V). Patients with severe respiratory failure and sepsis are in a 
hyperinflammatory condition, and paper IV showed in a prospective, observational pilot study that 
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the proportions of mature and immature polymorphonuclear leukocytes differ significantly between the 
early and late phase of ECMO treatment. 
Paper I 
Thirteen patients with confirmed pandemic influenza A/H1N1-induced severe ARDS were treated with 
ECMO at the ECMO Department of the Karolinska University Hospital, Solna, Sweden. All patients 
survived to discharge from ECMO treatment, and 12 patients were still alive three months after 
discharge from hospital (92%). This study is the largest single center study on patients treated with 
ECMO for H1N1 respiratory failure. Other single or multicenter studies have reported survival rates 
between 35% and 79% [52, 53]. Several factors may have contributed to the results presented in paper I: 
a) we cannulated and started ECMO before and continued during the transport from the referring hospital 
as conventional transportation to an ECMO center is associated with substantial mortality; b) we used a 
sufficient oxygen supply by ECMO to meet the oxygen requirements of the patients, making it possible 
to establish low airway pressure, low tidal volume ventilation and even accepting totally atelectatic lungs 
and discontinuation of ventilation in case in which  pneumothorax occurred; c) we changed the circuit 
from veno-venous to veno-arterial ECMO when right heart failure occurred; and d) needed major 
surgery was performed, although reoperation due to postoperative bleeding was required in one case. 
 
Paper II 
PreECMO hospital length of stay; creatinine, bilirubin and hematocrit values and mean arterial blood 
pressure were significantly associated with mortality in patients treated with vv ECMO for influenza A  
H1N1 2009. Based on these finding, the ECMOnet score was developed. This score had a high accuracy 
for the prediction of the mortality risk in the patients treated with ECMO (ROC analysis: c = 0.857, 95% 
CI, 0.754–0.959, p < 0.001). The probability of correctly classifying patients with this score was 75%, 
where a score of 4.5 was the most appropriate cutoff for mortality risk prediction. In the external 
validation group, the score also had a good capacity to distinguish survivors from non-survivors (ROC 
analysis: c = 0.694, 95% CI, 0.562–0.826, p = 0.004). Five of 13 patients from paper I had a score of 
more than 4.5, i.e., the estimated mortality was > 80 % (Table 22). All these patients survived ECMO 
treatment.
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Table 22. The ECMOnet score of 13 patients treated at the ECMO Centre Karolinska who were 
part of the external validation group 
 
 N 
 
Score Missing 
values 
ECMO 
survival 
1 6 - yes 
 
2 4 - yes 
 
3 3 - yes 
 
4 2 3 yes 
 
5 1 3 yes 
 
6 8 1 yes 
 
7 4 - yes 
 
8 1 3 yes 
 
9 1 3 yes 
 
10 1 3 yes 
 
11 6 - yes 
 
12 8 1 yes 
 
13 6 - yes 
 
 
Furthermore, this score was validated in the context of ECMO-treated patients, a relatively 
homogenous group of patients with severe respiratory failure due infection with H1N1. Whether  
the ECMOnet score has the same accuracy in other patient populations has not been proven and 
needs to be investigated. Therefore, the use of this score for decision making for initiating ECMO 
treatment should be taken with great caution.   
 
Paper III 
This is the first study reporting the long-term neurological outcome of permissive hypoxemia in 
ECMO-treated patients and, furthermore, it is the first reporting the long-term neurological 
outcome in patients treated with ECMO during the 2009/2010 H1N1 pandemic. We found that 
cognitive function, including memory, was within two standard deviations of the mean FSIQ in a 
healthy reference population despite all patients being hypoxemic before ECMO and subjected to 
permissive hypoxemia during the first 10 days of their treatment or the entire treatment, 
respectively. 
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All patients had normal preoxygenator venous saturations and blood lactate values, which indicated 
normal tissue perfusion, i.e., no tissue hypoxia. 
Other studies found a statistically significant correlation between cognitive dysfunction and hypoxemia, 
i.e. a SaO2 < 90%, but it is not clear whether hypoxemia was the underlying cause of these sequelae 
[46, 47]. 
Previous laboratory studies have shown that CaO2 and not PaO2 is the most important factor for 
cerebral oxygenation and perfusion [54]. In our study, mean CaO2 was kept at 14.3 ± 1.9 ml/100ml by 
increasing hemoglobin concentration by erythrocyte transfusions. One potential drawback with this 
approach is the risk of transfusion-related complications. However, in a recent study in septic patients 
without hypoxemia comparing two transfusion policies resulting in two levels of hemoglobin 
concentrations, there were no differences in complications between the groups, and in another study in 
patients with cardiac surgery, likewise without hypoxemia, the mortality rate even decreased with 
higher hemoglobin level and thus a higher number of transfusions [55, 56]. Moreover, a low preECMO 
hematocrit value (35% versus 30%, p = 0.01), i.e., a low hemoglobin value, was significantly 
associated with ECMO mortality, as shown in paper II of this thesis.  
 
Paper IV 
In this pilot study in six ECMO-treated patients with severe ARDS and sepsis, we observed a 
statistically significant difference in the proportions of CD16hi and CD16int from ECMO early to 
ECMO late in the surviving patients. In contrast, we could not find any significant changes in 
traditionally used markers of inflammation, CRP, PCT, and WBCs. Although we did not assess the 
inflammatory role of the PMNs in either the lungs or in the blood, our findings of high levels of GM-
CSF combined with a high proportion of CD16int in the early phase of ECMO confirm the important 
role of CD16int in the first phase of ARDS [9]. As expected, the expression of the receptor CXCR1 was 
considerably increased on these cells. This receptor has a high affinity to the chemokine IL-8, which 
plays a pivotal role in the chemoattraction and activation of the PMNs [57, 58]. Thus, the combination 
of increased levels of CXCR1 on CD16int and the IL-8 at the beginning of the ECMO treatment 
underlines the role of immature PMNs in the inflammatory response. The simultaneously increased 
anti-inflammatory cytokines interleukin 10 (IL-10) and interleukin 1 receptor antagonist (IL-1ra) could 
be seen a counter-response to this pro-inflammatory activity [59, 60]. In contrast, in the non-surviving 
patient CD16int, PMNs and anti-inflammatory cytokines were higher in the late than they were in the 
early ECMO phase. One could speculate whether this could be due to an inadequate anti-inflammatory 
activity in a situation with increased inflammation. In the surviving patients, we found that the 
cytokine IL-15 and chemokine Mip 1β decreased during ECMO treatment. Although these results 
were incidental findings that could have been due to chance, they are in accordance with the notion 
that the survivors’ immune responses were appropriate. Mip 1β is a chemokine, which is produced by 
macrophages during endotoxin stimulation. It activates PMNs and therefore has a pro-inflammatory 
effect [61]. The IL-15 is secreted by phagocytes and regulates the activation of natural killer cells, 
which are necessary for the immune response [62].  
The course of the proportions of immature PMNs occurring in the peripheral blood in patients with 
severe inflammatory conditions like severe ARDS or sepsis treated with ECMO has not previously 
been investigated. The present study suggests that it may not only have a diagnostic but also a
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prognostic value in these patients, but this study has several limitations.  First, the sample size is 
small, and although the study was prospective, we were only able to get full data sets from a fraction 
of the patients eligible for the study. Therefore we cannot be certain that the patients included are fully 
representative of the ECMO patient population. Consequently, general conclusions are difficult to 
draw, and the findings should be interpreted with great caution. Second, the pro-inflammatory effect 
of the ECMO treatment itself has not been studied in this context. Extracorporeal circulation induces 
the activation of PMNs and increases cytokine concentrations, which could have affected our findings 
[63].  
 
Paper V 
This review could not identify any RCT, nested case-control study, or longitudinal observational 
study, i.e., studies with high quality evidence that investigated the relationship between hypoxemia in 
ventilated patients with ARF and/or ECMO treatment and cognitive outcome. We found six reports 
with low evidence grades that investigated some of our study questions. In these, the proportion of 
patients with cognitive dysfunction ranged from 70% to 100% at discharge (Hopkins 1999 and 
2004/2005) to 23% to 57% in patients with ARF. The follow-up was 1 to 12 years after discharge.  
Two studies investigated the correlation between hypoxemia and cognitive function by assessing the 
duration of hypoxemia and correlating it statistically with cognition [46, 47, 48]. Two studies reported 
an association between hypoxemia (SaO2 < 90%) during treatment and cognitive dysfunction in 
survivors from severe ARF/ARDS, one at discharge and one at 12 months after discharge [46, 47]. In 
the study by Mikkelsen et al. mean SaO2 levels were similar, 94.2% in the groups with “higher” (86 
mmHg) and with “lower” (71 mmHg) PaO2. In fact, this SaO2 level is not commonly considered as 
hypoxemic. Moreover, in a secondary analysis, Mikkelsen et al. could not verify their previously 
found association [51]. The two remaining studies by Rothenhäusler et al. and Risnes et al. did not 
assess the degree of hypoxemia but dealt with patients treated with ECMO for severe ARF [47, 48]. 
The study by Risnes et al. in survivors of ECMO treatment for ARF and severe circulatory failure 
showed that patients treated with v-v ECMO for ARF had less cognitive dysfunction compared with 
patients treated with v-a ECMO. Indeed, the patients treated with v-v ECMO had similar rates of 
cognitive dysfunction as reported in non-ECMO-treated patients, namely between 40% and 50% at 1 
year after discharge from hospital [48]. Rothenhäusler et al. did not find that ECMO treatment was 
correlated with cognitive dysfunction [49].  
 
Limitations 
In this thesis, I have focused on the treatment of H1N1-infected patients with severe respiratory 
failure treated with extracorporeal membrane oxygenation. The problem with my approach to study 
such patients in a single center setting is the low number of patients that can be included. Thus, my 
studies, except study number V, can be considered to be case series. Consequently, the results I have 
been able to obtain can only give an indication that our treatment policy is 
acceptable and  as good as that in other ECMO centers. However, I believe that it is ethically 
questionable to perform a randomized controlled study to evaluate whether the outcome from ECMO 
treatment versus conventional ventilation in patients referred to our internationally 
 44 
recognized ECMO unit due to two reasons; 1) the conventional treatment used before initiating 
ECMO by definition has failed, and it is highly probable that the patients will not survive without 
ECMO. In this context it is important to recognize that the patients are incompetent to give informed 
consent by themselves due to sedation and the disease process. And 2) the number of patients treated 
in our unit is too small to get adequate statistical power to conclusively decide whether ECMO is 
associated with improved outcome regarding survival and cognitive function. Unfortunately, the few 
randomized studies regarding ECMO have not been conclusive, and no studies as we found out in the 
systematic review regarding hypoxemia/ECMO treatment have been able to pinpoint whether 
hypoxemia or ECMO treatment are associated with long-term cognitive dysfunction. Thus, in my 
view, the limited evidence I provide in my studies is as good as that presented in the current literature. 
Nevertheless, my studies should be interpreted cautiously due to these limitations. 
 
 
6 CONCLUSIONS 
 
• Patients treated with ECMO for H1N1 induced acute respiratory failure have a good 
 short- and long-term outcome in terms of survival and cognitive functioning. To achieve 
 positive results with this treatment option, it is necessary to provide an ECMO 
 transportation service that allows initiating ECMO at the referring hospital and thereby 
 stabilizing  the patient before and during conventional transport and possibly reducing 
 transportation-associated mortality risk. Other factors possibly influencing the outcome 
 are the change from v-v ECMO to v-a ECMO in case of right ventricular incompensation, 
 performing major surgery when necessary, and treatment of these patients in specialized 
 ECMO departments with sufficient case loads.  
• Survival of ECMO patients is related to preECMO extrapulmonary organ function and 
 the ECMOnet score may be helpful in estimating the mortality risk in ECMO patients 
 before initiating ECMO. Using the score to deny ECMO to patients fulfilling the criteria 
 because their mortality risk would be too high does not seem to be appropriate, and as the 
 score only has been studied in H1N1 patients, it needs to be confirmed in larger studies 
 with a more heterogeneous patient population. 
• Despite a severe hypoxemic condition before and during ECMO, the follow-up study of 
 seven ECMO-treated patients with influenza A/H1N1 infection had normal cogntive 
 function 3.2 years after ECMO. These results indicate that the ELSO recommendation of 
 a SaO2 down to 80% during ECMO may be reasonable with respect to long-term 
 cognitive outcome if this level allows preservation of adequate organ perfusion. Because 
 of the small sample size, further studies in this category of patients are needed. 
• In our prospective, observational pilot study, normalization of the proportions of CD16hi and 
CD16int in patients treated with ECMO for refractory ARDS with sepsis was associated with 
an improvement of the clinical situation in survivors. Thus this time course of these 
proportion could be used as a prognostic marker in these patients. The predictive value of the
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clinical routine measurements of CRP, PCT, and WBCs was limited in the patients in this 
pilot study. Due to the small sample size, our study is only hypothesis generating. This 
observation needs therefore to be evaluated in studies with larger sample sizes. 
• Our systematic review did not identify any high quality study answering the question 
whether hypoxemia during conventional mechanical ventilation or ECMO treatment, or 
ECMO itself, is associated with long-term cognitive impairment. However, from low 
evidence data we cannot exclude that hypoxemia could influence cognitive dysfunction at 
discharge from hospital in patients treated with only mechanical ventilation. We consider 
that it is necessary to examine the question whether hypoxemia and interventions such as 
ECMO treatment have effects on short- and long-term cognitive outcome in future RCTs. In 
addition, further evidence is required to determine the effect of other factors that could affect 
cognition, especially the modifiable factors, like metabolic state, oxygen transport, and organ 
perfusion pressures. 
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